Canaccord Genuity Maintains a 'Buy' on OraSure Technologies (OSUR); Q2 Preview: Build on its Momentum

July 12, 2012 1:38 PM EDT Send to a Friend
Get Alerts OSUR Hot Sheet
Price: $8.30 -3.6%

Rating Summary:
    12 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 38 | New: 6
Trade OSUR Now!
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on OraSure Technologies (NASDAQ: OSUR) price target of $14.00.

Analyst, Jeffrey Frelick, said, "We expect OraSure to report Q2/12 sales of $22.5M (+18%), in line with the consensus estimate, and EPS of $(0.09), matching consensus."

"We expect OSUR to build on its momentum from 2011, as we expect OSUR’s first-ever rapid CLIA-waived HCV test to result in $14M and $24M in HCV revenue in 2012 and 2013, respectively. In addition, OSUR obtained FDA approval for its HIV OTC test earlier than we forecasted. We expect OSUR can generate HIV-OTC revenue of $7M and $18M in 2013 and 2014, respectively."

For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.

Shares of OraSure Technologies closed at $12.51 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Canaccord Genuity

Add Your Comment